BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

Attralus debuted on Monday with a $25 million series A round from venBio Partners, a pan-amyloid imaging agent and a pair of candidates that can be developed for multiple types of systemic amyloidosis.  The company’s...
BioCentury | Nov 19, 2019
Company News

Nov. 18 Company Quick Takes: Eidos spikes on latest amyloidosis readout; plus Janssen, Pfizer, Tricida, BMS-Celgene

Eidos hits new peak on Phase II extension readout in amyloidosis Eidos Therapeutics Inc. (NASDAQ:EIDX) shares climbed $8.47 (18%) to $55.02, touching an all-time intraday high of $55.25, after the company said results of a...
BioCentury | Oct 30, 2019
Financial News

Pfizer surprises Street with Vyndaqel sales, uptake

...$5.14 (12%) to $47 on Tuesday, close to its all-time high of $49.72. The company’s AG10...
BioCentury | Oct 5, 2019
Finance

Seeking bright spots in 4Q19 amid continued underperformance

...therapy. Linimeier said he’ll be looking out for top-line Phase II data in mid-November from AG10...
BioCentury | Sep 17, 2019
Company News

Sept. 13 Company Quick Takes: FDA issues warning on CDK4/6 drugs; plus Castle Creek to buy Fibrocell and Eidos rebuffs BridgeBio

...66.6% of Eidos’ outstanding common stock, submitted the bid on Aug. 8. Eidos is developing AG10...
BioCentury | Sep 14, 2019
Company News

Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

...granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) exclusive rights to develop and commercialize transthyretin-mediated amyloidosis (ATTR) candidate AG10...
...TTR - Transthyretin; VEGF-A - Vascular endothelial growth factor A Mary Romeo, Assistant Editor abicipar pegol (AGN-150998, MP0112) AG10...
BioCentury | Aug 9, 2019
Company News

BridgeBio looks to fully own its CV subsidiary Eidos

...and Eidos; he declined to comment. BridgeBio launched Eidos to develop transthyretin-mediated amyloidosis (ATTR) candidate AG10...
...million in June, finished Friday with a valuation of about $3.2 billion. Elizabeth S. Eaton, Staff Writer AG10...
BioCentury | Mar 1, 2019
Clinical News

Eidos starts Phase III of AG10 in TTR amyloid cardiomyopathy

...Eidos Therapeutics Inc. (NASDAQ:EIDX) began the two-part Phase III ATTRibute-CM trial evaluating AG10 to treat transthyretin...
...of cardiovascular-related hospitalizations at 30 months. The placebo-controlled trial will evaluate twice-daily 800 mg oral AG10...
...I-III symptoms. AG10 is a small molecule designed to stabilize TTR. Last year, Eidos said AG10...
BioCentury | Nov 16, 2018
Clinical News

Eidos' AG10 leads to >90% TTR stabilization at day 28 in Phase II

...Eidos Therapeutics Inc. (NASDAQ:EIDX) said AG10 led to >90% stabilization of transthyretin (TTR) at day 28...
...all treated patients in a Phase II trial to treat symptomatic TTR amyloid cardiomyopathy. Twice-daily AG10...
...at the 800 mg dose vs. a decrease of 7% for placebo (p<0.0001 for both). AG10...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...year end from a Phase II study of AG10 to treat transthyretin (TTR) amyloidosis cardiomyopathy. AG10...
...Group plc (LSE:DNL) Chronocort Congenital adrenal hyperplasia Ph III data 4Q18 Eidos Therapeutics Inc. (NASDAQ:EIDX) AG10...
Items per page:
1 - 10 of 24